Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease
It is concluded that dulaglutide causes significant reductions in urinary albumin and modulates EMT-related proteins thereby ameliorating the decline in kidney function in patients with type 2 diabetes and DKD.
Authors
- Xiaohua Chou
- Miaoyan Liu
- Daoli Jiang (ORCID: https://orcid.org/0000-0002-5566-6585)
- Jiaxin Shen (ORCID: https://orcid.org/0000-0002-3153-8466)
- Fandong Meng (ORCID: https://orcid.org/0000-0001-8033-0816)
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2025-01-10
- DOI
- https://doi.org/10.5414/cp204632
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00